Search This Blog

Wednesday, June 24, 2026

Moscow Oil Refinery Faces Six-Month Shutdown After Relentless Ukrainian Drone Attacks

 Moscow's largest oil refinery is expected to remain out of service for at least six months after suffering significant damage in a series of Ukrainian drone attacks this month, according to Reuters, citing sources familiar with the matter, after Zelensky earlier vowed to bring the war to Russian territory. Kiev and the West are flirty with massive Russian retaliation at this point, which is precisely what Putin has vowed.

The refinery is located on the southern outskirts of the Russian capital and a major fuel supplier to the whole region. It was struck at least twice before this month - as dramatic and intense eyewitness videos captured - forcing operations to halt. Meanwhile via Newsquawk: 

Russia has reportedly asked for 50k tonnes of gasoline from Kazakhstan to help ease domestic fuel shortages, according to sources.

Several attacks on Moscow refinery in a matter of days, via AFP

"Repairs will take at least six months," one source said, describing the extent of the damage at the Moscow Oil Refinery.

The Gazprom Neft operatd facility processed 11.6 million metric tons of crude oil in 2024 and produced roughly 2.9 million tons of gasoline and 3.2 million tons of diesel fuel, according to public data.

It comes at a sensitive moment Russia continues to grapple with fuel supply challenges. At the moment, the Crimean peninsula is witnessing unprecedented government restrictions on selling gas to civilians, as well as half the population suffering an electricity blackout due to major Ukrainian drones strikes on Kerch port, and in particular damage to the large thermal power plant there.

Also, Russian Deputy Prime Minister Alexander Novak said this week that Moscow is considering a ban on diesel exports to stabilize domestic markets amid emerging shortages.

Ukraine's Security Service (SBU) previously claimed responsibility for a June 16 strike that reportedly damaged the refinery's primary oil-processing unit, described by Ukrainian officials as the plant's "heart." That's when the facility first reportedly suspended operations following the attack.

Two days later, Ukraine launched another large-scale drone assault on Moscow. Russian authorities reported hundreds of drones targeting the capital, resulting in fires at multiple locations.

Since international crude oil prices surged following the war in the Middle East centered on Iran, Russia has boosted its oil revenues as not only prices have jumped - but Russian oil was made desirable in India again - thanks to American waivers for sales of Russia’s crude already loaded on tankers in connection to easing the global crisis due to the Iran war.

Some reports have suggested Russian 'friendly fire' initially hit the Moscow refinery, the result of errant local anti-air missiles:

Rather than back down in the face of Moscow's new threats of "massive group strikes" on Ukraine, it seems Ukrainian forces are flexing with yet more attack waves. 

The Kremlin has long believed that Ukraine can't accomplish such sophisticated long-distance strikes on its own, but that it has had significant targeting help from US and Western allied intelligence.

https://www.zerohedge.com/geopolitical/moscow-oil-refinery-faces-six-month-shutdown-after-relentless-ukrainian-drone-attacks

Absci prices $100 m underwritten common at $7.41 per share to fund advancement of ABS-201

 

Absci prices $100 million underwritten common stock offering at $7.41 per share to fund advancement of ABS-201

  • Eli Lilly and leading institutional investors are participating in the underwritten common stock offering.
  • Proceeds will also be used for general corporate purposes.
  • Absci reports positive interim Phase 1 data from HEADLINE trial of ABS-201.

Haisco licensing deal for two late-stage assets sparks NVCT

 

Haisco licensing deal for two late-stage assets sparks NVCT 22% surge

  • Nuvectis announced ex-China rights to NXP100 (Complement Factor B inhibitor for PNH/IgAN/LN) and NXP200 (paradox-breaker BRAF inhibitor for mutated cancers) on June 22.
  • Deal includes up to $40M upfront/near-term payments to Haisco, $1.421B potential milestones, and tiered royalties; transforms NVCT into late-stage developer.
  • HC Wainwright raised PT to $39 from $13; Lucid Capital to $22 from $18, citing pipeline expansion into multi-billion-dollar markets.
  • Stock hit 52-week high near $18.24 with elevated volume; 19.6% gain on June 23 extended into June 24 trading.
  • NXP100 has Phase 3/2 data in China; NXP200 shows CNS penetration and responses in BRAF-mutated tumors per release.
  • Analysts and retail buzz highlighted best-in-class potential and strategic fit with existing oncology focus.

CUPR FDA clearance for MEDIFLY maggots drives

 

Momentum from June 15 FDA clearance for MEDIFLY maggots drives 79% CUPR premarket surge

  • Cuprina received U.S. FDA 510(k) clearance on June 15 for MEDIFLY, first-ever for Lucilia cuprina maggot debridement product for chronic wounds (GlobeNewswire).
  • Prior surges exceeded 150% and 100%+ on FDA news plus June 12 Nasdaq compliance regain; stock remains highly volatile post-reverse split.
  • Closed June 22 at ~$3.93 (down 10%); today's premarket pop to near $7 area reflects low-float momentum trading.
  • Recent X/trader chatter highlights price targets ($5) and support levels with no new announcements cited.
  • Maggot debridement therapy (MDT) is established for wound care; clearance expands U.S. commercialization potential for biomedical firm.
  • No fresh company press release or fundamental update identified for June 23-24 specifically.

Peer-reviewed cryoablation study and Japan expansion news drive ICCM

 

Peer-reviewed cryoablation study and Japan expansion news drive ICCM 30% surge

  • June 23 PR highlighted International Journal of Surgery article (top-3 ranked) validating ProSense advantages over RFA for early-stage breast cancer.
  • Article reports 99.02% recurrence-free rate in >600 patients (up to 17-year follow-up); comparable outcomes to breast-conserving surgery for tumors ≤2cm.
  • Cryoablation enables local anesthesia and visible adjustable ice ball; RFA requires general anesthesia and offers poorer control.
  • IceCure preparing to present at Japanese Breast Cancer Society meeting in Kyoto, June 25-27, 2026.
  • Distributor Terumo plans PMDA regulatory submission for breast cancer indication in Japan in second half of 2026.
  • Builds on prior 70% U.S. ProSense install-base growth post-FDA clearance and $5.5M institutional placement that sparked 200% rally.
  • Small-cap volatility amplified move with trading halts; retail/X chatter cited Japan catalyst and short squeeze dynamics.
  • Explanation based on company PR, Yahoo Finance data, and market reports; no other discrete catalyst identified for exact June 24 session.

Pulsenmore partners with Ouma Health to integrate FDA-authorized home ultrasound

 

Pulsenmore partners with Ouma Health to integrate FDA-authorized home ultrasound platform into Ouma’s U.S. virtual maternity care services

  • Partnership expected to expand Pulsenmore’s presence in the U.S. maternal health market.

https://www.zerohedge.com/energy/googles-dual-nuclear-technology-strategy-takes-shape-kairos-and-ge-vernova